On this page, you will find up-to-date information on U.S. FDA-approved treatments available for Epidermolysis Bullosa (EB), providing valuable insights to help individuals and their families make informed decisions about managing EB.
Over the years, significant advancements have been made in therapy development to alleviate the most debilitating symptoms of Epidermolysis Bullosa (EB). As of May 2023, the first therapy to treat Epidermolysis Bullosa (EB) has been approved by the U.S. Food and Drug Administration (FDA).
There are several other treatments being evaluated in clinical trials. Learn how you or your loved one can participate in these trials.
Available Treatments
VYJUVEK™
Name: VYJUVEK™ (beremagene geperpavec-svdt)
EB Type: Dystrophic Epidermolysis Bullosa
Year of Approval: 2023
Approved Age: 6 months or older
Learn More
FILSUVEZ®
Name: FILSUVEZ® (birch triterpenes) topical gel
EB Type: Junctional and Dystrophic Epidermolysis Bullosa
Year of Approval: 2023
Approved Age: 6 months or older
Learn More
